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ATYPI CAL OHOLINES!ERASE
At least two distinct torms of cholinesterase exist
within the bodl'. Oho11nesterase Il, also known as specific;
cho11nesterase, true- cholinesterase, E-type; cholinesterase,
and acetyl cholinesterase is present in red cells and nervous tissue. I.ts function is poorly understood but it
apparently has both muscarinic and nicotinic functions') in
neurohumoral transmission~IOholinesterase II, also known
as atypical cholinesterase, nonspecific cholinesterase,
pseudocholinesterase, S-type cholinesterase, and acyl-cholineacyl-hydrolase, is synthesized in liver and is present in
plasma and many other tissues?'
The estimation of plasma cholinesterases mal' have clinioal value in such conditions as liver amldb11I6,rl' tract
diseases, malnutrition, fluorophospbate ester pOison1ng and
1n patients being treated w1th thio-TEPA for cancer. Plasma
oholinesterase levels may also be reduced atter ingestion of
such drugs as chlorpromaz1ne, morphine, estrogens, cortisone1
quinine, prost1gmln, physostigmIne. and procalne.2~
a.rum cholinesterase hydrolyzes succ1nylchollne,;as 1t
does prooaine and other eS,ters of benzoic acid. In1 t1all7, it
istranstormed to succ1n,I monocholine and cho11ne. Sllcc1nyl
monochollne, a weak neuromuscular blocker about 1/20 as
potent as succ1nylchol1ne, 1s in turn hydrolyzed to succ1n1nc
aoid and choline. Under ph;rsiolog10 conditions the tirst reaotion

o~curssix

times more rapidly than the second. Serum cho-

linesterase acts only wbilee sJlccinylcholine is present in
the blood. Enzymatic activity increases with a rising concentration of the drugs. fhe rate of hydrolyses is rapid,
about 90% of the injected dose is destroyed in the first
minute; heme enzyme activity is of importance only briefly
but serves to limit the amount of relaxant that reaches . ttle
neuromuscular end-plate. T.rminatlon of aotion is probably
caused by diffusion from ttle end-plate into the interstitial
fluid.
It has been noted that oertain individuals given succinyl-

oholine undergo profound protracted apnea responsive only to
assisted ventilation. In these cases, known as "suxamethonlumit'lpneaM,
the plasma pseudocholinesterase levels were found to be lower
than normal. It was noted that they aalso demonstrated Invitro
reststance to enzymatic inhibition by such compounds as dibucaine, fluorlie:and If-butanol. This inhibition was not present
in patients lacking this susceptibility to succinylcholine):.4,6
The need for determination of this plasma enzyme prior to administration of suoh anesthetic agents is aovious.
Genetic studies in families exhibiting this peouliarity
in the pseudocholinesterase system revealed that the plasma
levels tended to cluster in at least three areas.

I~

has sub-

sequently been olarified that the genes for the first found
loci of pseudocholinesterase (represented by El ) are probably

alleles of the same locus. By describing the patients as E1 U
(usual), I l a (atyp1cal), Ils (s11ent), and :&:1t1- (fluoride,)
ten geno*1pes bave been described. A patient wbo i8 homozygous
for

Bill 1s usual or normal and will show sat1sfactory inhi-

bition of serum cholinesterase by dibucaine, tluoride and
B-butanol. Those who are homozygous . tor Ii' are atypical and dtt
not show satisfactory invitro inhibit10n of tne1r cholinesterase
level. Tnese patients are detini**iy at r1sk to develop euxamethonium apnea although the attack rate is not 100% and is
somewhat dose related. The absence of plasma pseudocholinesterase
(homozygous I I S ) demonstrates the so-called silent gene in
whicn no pseudocholinesterase activity is demonstrated in
plasma. These cases are extremely rare.}
H.tero~ygotes, that is combinations of Bl U and Ila show

partial invitro

~nhibition

but

.t~

not to the degree of the

true atypicals. These patients are apparently not att risk to
develop suxamethonium apnea.
N~rmall1

apprOXimately 80% of the pseudocholinesterase

activity in plasma can be inhib1ted invitro by posit1vely
charged quaternary n1trogen conta1ning molecules such as d1buca1ne. The per cent 1nh1b1t1on is inown as the dibucaine
number. Surveys of the general papule. tion reveal that 94% of
people tested show about 80% inhibition of their pseudocholinesterase level by dibucaine and can be classified as
homozygous for Bl~. Approx1mately ,_ will show 4G-60_ inhi-

-4b1t1on and ar. apparently heteroSTgotes show1ng a comb1nat1on
of El U and Ila or E fl • only 1 1n 4,000 pat1ents will show
l
only 20% 1nvitro 1nhibit1on by dibucaine, are homozygous for
I a , and are definitely at risk for suxamethonium apnea. The"
I
negatively charged fluoride ion may also be used as an invitro
inhibitor: This inhibition 1s 1mmediate, constant, and reversible, as studied by dialysis and dilution techniques. It is
presumably a direct effect by the fluoride ion and not by complexing with such metals as megnesium and calc1um

or phospahte.

The relit10nsh1p of the fluoride and d1bucaine inh1bition
in heterozygotes has not been clearly established. It is
possible that they are biochem1cal facets representing the
same gene. However, studies of inhibitions by these two compounds have shown that in neter,zygotes (1 &. E1U).the inhi1
bition is relatively less by fluoride than by d1bucaine. 1
!boe neutral compound

.~bu~nol

has also beea used as an inh1-

bitor1 In all cases the atypical homozygotes as well as the
usual homo zygotes are clearly defined. Unfortunately the
def1nition of the

phenotypes is not always
clear nor separable depending on the inhibitor uaed. 6
het~ygotic

Laboratory methods for quantitating the amount of cholinesterase present 1n plasma measure enzyme activ1ty and do
not d1fferentiate between the normal and atypical variety.4Thus low enzyme levels may mean reduced amount of normal

-5enz;yme~or

the presence of the atypical enz;yme in varying

amounts.
~ny

substrates have been util1zed for the determination

of plasma true and pseudocholinesterases. Trlbytyr1n, acetylbeta-methylcho.11ne, benzoylcho11ne, phenylacetylcho11ne, and
acetylcholine have all been used. At that the cholinesterases
are relatively nonspec1fic and both also hydrol1ze a variety
of noncholine esters. Substrate$specificit7 has been poorly
defined but it is fairly well established that red cell true
cholinesterase will hydrolyze acetyl-beta-methylcholine but
not benzoylcholine, while the plasma pse.udochol1nesterase
will react in Just the opposite faSb.1on~'
The cases which were studies 1n this paper underwent
varying degrees of suxamethonium apnea after administration
of succinylcholine. Tb.e pseudocholinesterase activity in
plasma of these individuals as well as members of their
tamilies was determined by the method to be described.Por
controls, approximately 30 normal individuals were tested
utilizing the same procedure.
Method
The method for determination of atypical forms of pseudocholinesterase used in this study was that of Kalow and
Genest."Oholinesterase activity was determined by ultraviolet spectropb.otometry at 240 nanometers using 5XIO-5 K
benzoylcnoline, buffered at pH 7.4, as substrate. The Bero

order reaotion was determined with and without the addition
of dibucai:iLu The degree of inhibition expressed as a per
oentage was recorded as the "dibuoaine number".
Benzoylcholine is a relatively stable compund showing
an absorbence maximum at 240 nm. Enzymatic aotivity is determined kinetioally (time-rate) by observing the loss of absorbanoe as the benzoylcholine is hydrolyzed to henzoate and
choline. -.iatively large conoentrations of the produot,
benzoate, produce little absorbance at this wavelength. Benzoyl.
choline is a relatively resistant to spontaneous hydrolysis
except by the action of bacterial or fungal growth aand must
be stored at 50 0. Excess, substrate has an 1nhibitory effect
just as 1t does when acetylcho11ne is used to estimate true
ohvlinesterase. Por th1s

~son.

very dilute substrate con-

centrations were used. The deainllct'nn of benzoylcholin.:by
serum cholinesterase proceeds at least 35 times faster than
that of acetylcholine when substrate concentrations in the
order of lO-SX'are usedo
Human serum or plasma wasd1luted

USOl~ifl

MIlS phosi!io

phate buffer, pH 7.4, and added to benzoylcholine substrate
w1th and w1thout the addition of dibucaine as an inhibitor.'~
Oonstant time-rate spectrophotometric anaylsis was determined
at 240 nm using a Gilford 2000 record1ng speotrophotometer
w1th automatic cuvette changer, thermoregulator at 2S 0 0'., and
1 em square quartz ouvettes. Reaot1ons were observed over a

-1-

period ot 3 minutes and a ohange in absorbance per minute with
and without the inhibitor was determined. The dibuoaine number, that is, the peroentage of inhibition, was oaloulated
as 100 times jl-(deorease absorbance in presenoe of dibucaine
divided by decrease in aabsorbanoe without dibucaine)/. Total
esterase units were arbitrarily expressed as micromols ot
acetyloholine hydrolyzed by 1 co of serum in one hour at 370
and were arbitrarily compared to the hydrolysis of benzolycholine. The total value was not a part of the study other
than the observation that the homozygous atypicals tended to
have lower tatal,. a.bsorbance values than did normals.
case Studies
Qase 1. LR, 6-year.old whlite male. developed plJolonged
post anesthetic apnea while undergoing a hernia repair. His
dibucaine number was 18. The father and mother bad dibuoaine
numbers of 61 and 72 respectively_ Five siblings bad numbers

ot 71, 68, 71, 85. and 86. A llf.-year-old sibling had a D.N.
a! 28. Interestingly enough this sibling bad undergone a

hernia repair some 3 years before without inoident in which
succinylcholine was administered.
case 2. fL. 62-year-old female, experienced apprOXimately
8 hours post-anesthetic apnea While having a hiatal hernia

repaired. Her D.N., was 18. Normal siblings had dibucaine
numbers of 68, 66, and 84, but one 61-year-old sister had a
D.N. of 23.

-8-

Qase:: 3. BY, 55-;rear-old

femalit,~

experience4 profound 12

hour apnea after receiving succinylcholine during the course
of an intrAmedullary nail pinning of a fractured hip. Her D.B.
was 25. A son and grandson&:had numbers of 68, 67, gnd 86.
case 4. liD, Sr., 34-year-old male, experienced severe apnea
following succinylchoine administration while having a It.ernia
repair. His dibucaine number was 14. His children had

D~.~N.·S

of 61 and 66.
Results
BY' this method normal patients (homozygote. (11'11-B1U),::

tended to bave dibucaine numbers between 70-85% as did normals
whose total ma;r have been somewhat low secondary to liver
disease. Abnormal homozygotes (lla -E1a ) 'clustere4 between 16
and 25. Heterozygotes by the dibucaine mettod were noted to
be between 50 and 65.
It 1s interesting to note that the parents who were
apparently homo zygotes for the gene E1a had total cholinesterase
levels Significantly lower than the 0.040-0.050 Absorbance
uni ts per minute -- of the normal range, running from
O.025A to 0.030A per minute. It ls interesting to speculate
on the apparent heterozygotic nature of the .arious ralatives
studied.
Oonclusion
!be relationship of lnhlbitible pseudocholinesterase
activity in serum and suxamethonium appea appears well

-9defined although tbe norma,Fi function of plasJlllapselldocholinesterase is poorly understood. The methods available
for the determination of dibuca1ne 1nhibitable pseudocholinesterase are

reasonab~

simple and precise. Tlis

determination should be performed on all patients who have
had prior post-anesthetic apneic reactions themselves or
have a family history of a similar event.

Reterences.
lJ.. 01mason1, G.: Il1hibition ot Cholineaterases b7 Fluoride in Vitro:

Biochem Jo 99:133, 1965.

2 •. aroisser, V.W.: Serum Estero17tic Acti vi t7 in a Wide Variet1 of
Disease sta.tes with Special Reference to Pancreatic a.nd
Liver Disease. New Eng Ji Ked 274:129 (Jan 20), 1966.
3'.. ICalow,

1f..

Genest. K.: A Method for the Detection of Atlpical
Forms of Human Serum Oholinesterase Determination ot
Dibucaine Numbers: Oan J Biochem. Ph1siol 35, (1957).

4. blow. W., Genest, Ie.: Kinetic Studies: on the H1drol7sis ot
Bensollcho11ne b7 Human Sera Cholinesterase: Qi,n. Anaest.
Soc. Jr. 3 :22, 1956.
5. Hone, J.G.: Qualitative and Quantitative Defects of Pseudocholinesterase Activit7: Anaesthesia 22:55-68 (Jan), 1967.
6. Wang, R.I.H., Henschel, 1.0.: Semiquantitative Determination
ot Oholinesterase Activit7 in Human Plasma: Anesthesla
Analgesia 46:3 Hal-June (1967).
. . .','
7. Whittaoker, M.: Differential Inhibition of Human Serum
Cholinesterase with N~But7l Alcohol: Recogn1tion of New
Phenotypes: Acta gent., Basel 18: 335-340 (1968).

